ABSTRACT
From preclinical research to the clinic, biomarkers play a significant role in building greater efficiencies into the drug development process. High rates of failure for new therapeutics and an ongoing need for stronger translational models have continued to drive biomarker advancement as a tool to demonstrate the safety and efficacy of new therapeutics while reducing development time and costs. Biomarkers hold a key role in advancing personalized medicine strategies and targeted therapies by stratifying patients, matching the right patient to the right clinical trials, and minimizing the potential for adverse effects.
